All In Biotech

Drug Trial Radar · NCT04219046

Evaluation of Naloxegol in the Prevention of POI After Cystectomy

Evaluation of Naloxegol, a Peripherally Acting µ-opioid Receptor Antagonist, in the Prevention of Postoperative Ileus After Cystectomy

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 2032

Primary completion

Jan 2032

Study completion Jan 2032

Sponsor

Lead sponsor
Institut Paoli-CalmettesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Postoperative ileus (POI) is defined as a transient reduction of bowel motility that prevents effective transit of bowel content and tolerance of oral intake following surgical interventions, especially after radical cystectomy. It remains a major factor associated with postoperative morbidity, length of hospital stay and medical costs. In order to optimize perioperative care for patients undergoing radical cystectomy in a context of an ERAS (Enhanced Recovery After Surgery) program, we will evaluate the effectiveness of systemic pharmacologic opioid antagonist treatment.

Conditions

  • Bladder Cancer
  • Cystostomy; Complications

Interventions

  • Naloxégol oxalateDrug

    Oral administration once daily

  • Placebo oral tabletDrug

    Oral administration once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time of hospital dischargeTime frame: Date at which treatment is initiated and date of hospital discharge (up to 12 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.